← All trials
NCT00565708
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2008
- Primary completion
- Dec 1, 2022
- Completion date
- Jun 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Government of SingaporeLead sponsor
- Government of SingaporeStudy chair
- Columbia UniversityStudy chair
- Australasian Gastro-Intestinal Trials GroupCollaborator
- INDOX Cancer Research NetworkCollaborator
- Government of SingaporeReponsible party - principal investigator
- University of OxfordStudy chair
- University of OxfordCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.